SELLAS Life Sciences Group, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SELLAS Life Sciences Group, Inc.
Stock Watch: A Word To Those Considering Unwrapping Clinical Trials Early
Halfway through a race, adding more athletes, taking out some hurdles and extending the distance until the finish would be unsporting in track and field. But not in clinical trials.
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
A Dramatically Changing Landscape In Acute Myeloid Leukemia
Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.
Asia Deal Watch: Astellas Acquires Global Rights To KaliVir Oncolytic Virus Candidate
Plus deals involving SELLAS/3D Medicines, Kyowa Kirin/InveniAI, JW/Voronoi, Y-mAbs/Takeda, Horizon Discovery/Sanyou, Sentinel Oncology/PharmaEngine
- Large Molecule
- Other Names / Subsidiaries
- Argonaut Pharmaceuticals, Inc.
- Galena Biopharma, Inc.
- RXi Pharmaceuticals Corporation
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.